Dr. Eric E Turcotte, MD
Claim this profileUniversité deSherbrooke
Studies Contagious Diseases
Studies Infectious Diseases
2 reported clinical trials
2 drugs studied
Affiliated Hospitals
Clinical Trials Eric E Turcotte, MD is currently running
NaF PET Imaging
for Bone Cancer
18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of universal tracer availability and higher costs contributed to the failure of 18F-NaF to systematically supplant bone scintigraphy as a standard of care. Recently, an isotope shortage crisis occurred and evidenced the need to have non-reactor-derived alternatives for many nuclear medicine procedures, including bone scintigraphy. Since 18F-NaF is cyclotron-produced, it could become a necessary alternative to bone scintigraphy in case of another worldwide isotope shortage. The study aims to evaluate the safety profile of 18F-NaF injection. Moreover, a patient registry will be compiled in order to perform sub-studies on 18F-NaF diagnostic performance on diverse bone and articular diseases.
Recruiting2 awards Phase 34 criteria
4FMFES-PET Imaging
for Breast Cancer
Estrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment. Pathological evaluations of primary tumor, axillary nodes, and metastases are the only confirmatory approach to ER status determination and are limited to known and accessible sites. However, it is known that many advanced breast cancer patients harbor diseases presenting inter-tumor or temporal ER heterogeneity, as ER expression can vary between tumor foci and can evolve during treatment and at time of recurrence, hence the need for whole-body, non-invasive assessment of ER status. In the last decades, 16α-\[18F\]fluoroestradiol (FES) was developed and evaluated as an ER-targeting positron emission tomography (PET) tracer. FES correlated with ER expression, and recently was shown to be able to predict hormone therapy response. Our Center designed and evaluated 4-fluoro-11β-methoxy-16α-\[18F\]fluoroestradiol (4FMFES), a successor PET tracer for ER imaging. Paired comparison during a phase II clinical trial showed that 4FMFES produced images of better quality, with less overall non-specific signal than FES. It resulted in a significantly improved tumor contrast and tumor detectability using 4FMFES-PET leading to increased diagnosis confidence in early-stage breast cancer compared to FES-PET. Those results demonstrated that, as of now, 4FMFES-PET is the best imaging modality worldwide for whole-body ER status determination, but further validations are necessary to position this method as a standard and essential tool for breast cancer management. Like what was observed for FES-PET, preliminary data suggest that 4FMFES-PET combined with FDG-PET will yield very high sensibility for breast tumor detection, each method being complementary. In continuity with previous work, we seek to expand our clinical knowledge of this high-potential diagnostic imaging through the following main objective: Launch a phase II clinical trial to explore the full potential and benefit of 4FMFES-PET in combination with FDG-PET for advanced ER+ breast cancer patients to demonstrate it is an essential tool for cancer management. This proposed project will focus on 3 specific aims: 1. Compare and complement 4FMFES-PET with FDG-PET and conventional imaging modalities, and evaluate how they improved prognosis and staging of ER+ advanced breast cancer patients; 2. Correlate 4FMFES/FDG uptake and staging with pathological data (histology, receptor status, grade), including distal biopsy metastases sampling; 3. Correlate 4FMFES/FDG uptake and staging with longitudinal outcomes (treatment response, progression-free survival, time-to-relapse) to determine which cohort of patient benefit most from 4FMFES.
Recruiting1 award Phase 29 criteria
More about Eric E Turcotte, MD
Clinical Trial Related16 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Eric E Turcotte, MD has experience with
- 18F-sodium Fluoride
- 4FMFES-PET
Breakdown of trials Eric E Turcotte, MD has run
Contagious Diseases
Infectious Diseases
Infections
Bone Tumors
Arthritis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eric E Turcotte, MD specialize in?
Eric E Turcotte, MD focuses on Contagious Diseases and Infectious Diseases. In particular, much of their work with Contagious Diseases has involved treating patients, or patients who are undergoing treatment.
Is Eric E Turcotte, MD currently recruiting for clinical trials?
Yes, Eric E Turcotte, MD is currently recruiting for 2 clinical trials in Sherbrooke Quebec. If you're interested in participating, you should apply.
Are there any treatments that Eric E Turcotte, MD has studied deeply?
Yes, Eric E Turcotte, MD has studied treatments such as 18F-sodium fluoride, 4FMFES-PET.
What is the best way to schedule an appointment with Eric E Turcotte, MD?
Apply for one of the trials that Eric E Turcotte, MD is conducting.
What is the office address of Eric E Turcotte, MD?
The office of Eric E Turcotte, MD is located at: Université deSherbrooke, Sherbrooke, Quebec J1H5N4 Canada. This is the address for their practice at the Université deSherbrooke.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.